Agenda

Date

July 21, 2020

Location

Dubai, UAE

Conference Agenda

Explore your options to connect, learn and be inspired from our speakers

Keynote Session:

Meetings International -  Conference Keynote Speaker Panjasaram Naidoo photo

Panjasaram Naidoo

Panjasaram Naidoo,University of KwaZulu-Natal, South Aftrica.

Title: Doctors' and pharmacists' knowledge, practices and barriers towards adverse drug reaction

Biography:

Panjasaram Naidoo, University of KwaZulu-Natal, Discipline of Pharmaceutical Science, South Africa.

Abstract:

Adverse drug reactions affect adults and children in varying magnitudes, resulting in mortality and morbidity. Reporting of ADR as part of pharmacovigilance activity, is vital to ensure positive health outcomes. This study aimed to assess the current knowledge, practice and perceived barriers towards adverse drug reaction (ADR) reporting amongst doctors and pharmacists in teaching hospitals situated in the eThekwini Metro of KwaZulu Natal, South Africa. Descriptive quantitative cross sectional study was conducted amongst doctors and pharmacists in 5 teaching hospitals in KwaZulu Natal, using a pre-tested questionnaire. Data was captured and analyzed using SPSS version 22 with  p values <0.05 considered statistically significant. Response rate was 76.5% [98] .  Whilst 100% of respondents were familiar with the term pharmacovigilance (PV), knowledge scores were low with 85.71% selecting the incorrect definition. No training was received by 68.36% of respondents on ADR reporting.  Even though 59 (60.2%) respondents indicated that their patient experienced an ADR, only 46.94% actually reported the ADR, with only 4 respondents satisfied with the feedback received from authorities after reporting an ADR.  Barriers were cited that prevented respondents from reporting ADRs.  Respondents were also not happy with the South African PV system. Over 70% of respondents indicated that they would participate in a PV training programme. Whilst the majority of pharmacists and doctors were familiar with the concept of PV, less than 50% reported an ADR. Many barriers were cited that contributed to respondents not effectively practising  PV  with the majority willing to participate in PV training to better their knowledge.

Meetings International -  Conference Keynote Speaker Prof Bernard M Y Cheung photo

Prof Bernard M Y Cheung

Prof Bernard M Y Cheung, University of Hong Kong, Hong Kong, China

Title: Pharmacovigilance through big data

Biography:

Bernard Cheung graduated from the University of Cambridge.  In 2007-2009, he held the chair in Clinical Pharmacology and Therapeutics in Birmingham.  He is now the Sun Chieh Yeh Heart Foundation Professor in Cardiovascular Therapeutics at the University of Hong Kong, and heads the Division of Clinical Pharmacology and Therapeutics.  He is an Honorary Consultant Physician of Queen Mary Hospital and the Medical Director of the Phase 1 Clinical Trials Centre.  He is an Honorary Professor at the Hong Kong University Shenzhen Hospital and a Visiting Professor of Shenzhen University. He is the Editor-in-Chief of Postgraduate Medical Journal.  He has 270 publications, 7500 citations and an h-index of 43.

Abstract:

In Hong Kong 70% of inpatient care is in public hospitals and most acute emergencies are treated in public hospitals. Therefore the most serious adverse drug reactions present to public hospitals. The Clinial Data Analyais and Reporting System (CDARS) has been capturing prescribing and dispensing data, as well as clinic and hospital attendance data, in Hong Kong for over ten years. This authentic source of information can link clinical events, at least the serious ones, with dispensing data. There are three recent examples of how we used these data. Firstly, contaminiated batches of generic valsartan were recalled in 2018 and we monitored the daily admissions due to stroke in the whole of Hong Kong. Fortunately, there was not the slightest signal of an abrupt rise in stroke. Secondly, we studied drug-related hypokalaemia (low plasma potassium) in the population. Of around 25000 hospitalisations due to hypokalaemia over a 10-year period, around 5000 were due to diuretics, one third of which were due to indapamide used for the treatment of hypertension. Lastly, we studied the incidence and risk factors for vancomycin-induced acute kidney injury. 1450 cases were identified over a five-year period. We identified trough vancomycin level, baseline renal function, organ dysfunction and concomitant drugs as risk factors These studies demonstrate the power of using computerised population medical data to investigate uncommon adverse effects of drugs. These big data can be used to complement the spontaneous reports from clinicians.

Oral Session 1:

  • Pharmacovigilance Significance & Scope Clinical Pharmacy and its Role in Treatment Pre-Clinical and Clinical Trials Biosimilars Pharmacovigilance and Risk Management Clinical Drug Toxicity and Biomarkers Pharmacovigilance for Herbal Medicines Pharmacoepidemiology Serotonin Pharmacology Pharmacogenetics and Pharmacogenomics Nano Pharmaceuticals
Meetings International - Pharmacovigilence 2020 Conference Keynote Speaker Albert M.Wu photo

Albert M.Wu

Albert M.Wu, College of medicine,Chang-Gung University, Tao-yuan, Taiwan.

Title: Lectins and ELLSA as powerful tools for Glycoconjugate Recognition Analyses

Biography:

Dr. Wu obtained his Ph.D degree with W. Pigman, who is one of the pioneers in glycoproteins, at New York Medical College; and had his postdoctoral training
at E.A. Kabat’s Lab for quantitative immunochemistry, Columbia University Medical Center, New York. He joined as a faculty position at Texas A&M
University in 1982; promoted as a full professor at Chang-Gung University since 1989; and as Emeritus Professor after 2011. Dr, Wu published over 120
glycoprotein and polyvalent glycotopes related papers. He is the chief editor for three volumes of Molecular Immunology of COMPLEX Carbohydrates 1 to
3 in Adv. Exp. Med. Biol. 228, 451, 705 (Springer Publisher). His major interests are (i) Glycan purification and characterization; (ii) recognition factors of glycans; (iii) combining sites of lectins and antibodies. He received many Outstanding Research Awards from government agents in Taiwan and U.S.A.  

Abstract:

Lectins, by combination of our established enzyme-linked lectin sorbent assay(ELLSA) and inhibition study, have been used as powerful tools in many glycoconjugate recognition researches. In this short review, four highlights are shared: There are (i) The recognition profiles of Gal/GalNAc specific lectins was updated and upgraded; (ii) Based on the cross specificities of applied lectins, a new classification system was introduced; (iii) Applications of lectins used to detect and to identify N-glycan and/or Tn glycotope in glycoconjugates were intergraded; (iv) The polyvalency of the glycotopes in glycans plays a critical role in glycan-lectin recognitions was established. This is an unexplored area of glycobiology and one of the most promised direction towards the coming age of glycoscience transformation.

Meetings International - Pharmacovigilence 2020 Conference Keynote Speaker Danyah Ahmed Katlan photo

Danyah Ahmed Katlan

Danyah Ahmed Katlan, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia

Title: Prevalence of Medication Related Problems in Kidney Transplant Recipients

Biography:

Danyah has completed her PGY1 at the age of 28 years at King Abdulaziz Medical City, Jeddah. She is an intyernal medicine clinical pharmacist at King Fahad Armed Forces Hospital, Jeddah. 

Abstract:

Kidney-transplant recipients have complex medication regimens due to chronic comorbidities, in addition to immunosuppressive medications leading to serious medication-related problems (MRPs). 1 Pharmacists play crucial role in identifying and assessing MRPs, providing education, monitoring and suggesting alternative medications. Studies reported that clinical-pharmacists joining renal-transplant clinics have potential impact on patients’ outcomes. 2,3 There is a paucity of data on prevalence of MRPs in kidney-transplant patients at King-Abdulaziz medical city, Jeddah. Therefore, the study aims to determine the prevalence and types of MRPs in kidney-transplant recipients at the outpatient clinics. Secondary objectives include identifying the pharmacological classes of medications contributed to the MRPs, the categories of MRPs and the predictors of MRPs. Methods: Retrospective cross-sectional, electronic health records review. Data were collected from June 2016 until June 2017. Inclusion criteria: patients above 18 years, receiving maintenance immunosuppressants and at least 3 months post-transplant. MRPs include: Drug-drug interactions, ADR, improper dosing, medications without clear indication, indication with no medication and Duplication. A sample of 80 patients was estimated to detect prevalence of 31%of one MRP at least per patient with 95%confidence interval, 5%precision, an alpha of 0.05. Results and conclusion: Screened patients were129. The mean age was 50±15.75, 66.3% were males. Most common comorbidities were hypertension(62%) and diabetes(42.5%). The prevalence of MRPs was 28.97% in 1393 medication orders reviewed. The most frequent MRP types were drug-drug interactions(46.1%) and duplications(16.7%), Most common medications involved were Immunosuppressive and cardiac-medications. Most significant predictors for developing >3MRPs were: number of medications and duration post kidney-transplant.

Meetings International - Pharmacovigilence 2020 Conference Keynote Speaker Abdeen Mustafa Omer photo

Abdeen Mustafa Omer

Abdeen Mustafa Omer, Occupational Health Administration, Ministry of Health, Khartoum, Sudan.

Title: Some Aspects of Fake and Counterfeiting of Drugs: Sudan Case

Biography:

Abdeen Mustafa Omer, Occupational Health Administration, Ministry of Health, Khartoum, Sudan, E-mail: abdeenomer2@yahoo.co.uk, Telephone: 0024946671.
 

Abstract:

The strategy of price liberalisation and privatisation had been implemented in Sudan over the last decade, and has had a positive result on government deficit. The investment law approved recently has good statements and rules on the above strategy in particular to pharmacy regulations. Under the pressure of the new privatisation policy, the government introduced radical changes in the pharmacy regulations. To improve the effectiveness of the public pharmacy, resources should be switched towards areas of need, reducing inequalities and promoting better health conditions. Medicines are financed either through cost sharing or full private. The role of the private services is significant. A review of reform of financing medicines in Sudan is given in this study. Also, it highlights the current drug supply system in the public sector, which is currently responsibility of the Central Medical Supplies Public Corporation (CMS). In Sudan, the researchers did not identify any rigorous evaluations or quantitative studies about the impact of drug regulations on the quality of medicines and how to protect public health against counterfeit or low quality medicines, although it is practically possible. However, the regulations must be continually evaluated to ensure the public health is protected against by marketing high quality medicines rather than commercial interests, and the drug companies are held accountable for their conduct.

Meetings International - Pharmacovigilence 2020 Conference Keynote Speaker Dr. Carolle-Laure photo

Dr. Carolle-Laure

Dr. Carolle-Laure KPOUMIE MD , phd in public health and social medecine, France

Title: RARE DISEASES AND HANDICAP: State : medical, social, health policy in developing countries. Case of Cameroon: about a case: Cushing's disease

Biography:

Dr. Carolle-Laure KPOUMIE MD , phd in public health and social medecine, has worked as pediatric assistant physician in pediatric’s department of faculty of medicine in Cameroon, as clinical researcher, scientific writing, public health, oncology, rares diseases,orphan drugs, handicap, internal medicine and continued her career in France. She participates in many congress with studies made in hospitals on relevant cases in the framework Studies and clinical research. She became head of department, director, where she continued her research, writing of treatment protocols in different departments for common pathologies encountered in her context, managing Epidemic crisis , rares diseases, participates in studies on neonatal mortality in underdeveloped countries. She work on ADR in hospital following drug administration, pharmacovigilance, vaccinovigilance, biovigilance, materiovigilance, pharmacovigilance in underdeveloped countries, articles, medical information and therapeutic safety, clinical trials, Post-marketing, and other’s studies.

Abstract:

Rare and orphan diseases are a reality throughout the world and a real public health problem in developing countries. The great precariousness in which the populations live increases their impact and their gravity by the absence of information, technical platform, means of detection, actual presence of research and clinical studies on these territories, lack of awareness of the detection, diagnosis, without forgetting that the means of care and prevention are sometimes inexistent or little known and especially expensive in countries where the populations are poor, without mutual or social security as in industrialized countries .
This work will focus on a patient case presenting a rare disease in this case Cushing's disease. A case that occurred in Cameroon in order to establish in a practical way this major and yet ignored, neglected issue in a health system with poor specialized structures, technical platforms, and without the support of the pharmaceutical laboratories that could with the health system of these poor countries set up a system of refueling in the sense of the social view the cost that requires the monitoring of these long pathologies that make autonomous living almost impossible, also life-threatening.
In Cameroon, there have been difficulties in the care and monitoring of this young patient since childhood through the phase of the pubertal transition, adolescence, to adulthood.
  It is therefore important to organize the follow-up of these patients, by developing specific programs of medical follow-up, psychological care, and social integration programs. Health policies should invest in better support.
 

Meetings International - Pharmacovigilence 2020 Conference Keynote Speaker Ali Awad Hamoud Aljeboory  photo

Ali Awad Hamoud Aljeboory

Ali Awad Hamoud Aljeboory, Pharmacology and Pharmacognosy Dept. Pharmacy College, Uruk

Title: Loranthus Europaeus is a Nano Alternative Medicine in Treatment of side effect of Chemotherapy of Breast Cancer.

Biography:

Ali Awad Hamoud Al-jeboory has completed PhD  at the age of 30 years from strathclyed University. He is  the professor  of Uruk  Pharmacy College , Uruk Private University. Ali Awad Aljeboory has published  50 papers and have had 5 discoveries of new drugs from natural products antihypertensive and heart tonic. In addition  serving as an editorial board member of Al-mustanseriah college of medicine journal. Also supervised 20 PhD graduated students in pharmacology, published two books in natural pharmacology and pharmacy . He was the director of Kufa college of medicine , head of the department of pharmacology ,pharmacognosy in scientific research  center , Head of the department of pharmacology and therapeutics department college of medicine Baghdad university. Head of department of pharmacology and Pharmacognosy Pharmacy College just now.

Abstract:

Cancer is responsible for one in eight deaths worldwide more than AIDS, tuberculosis, and malaria together. Natural product still continue to be important as source of novel drugs because these dugs does not need sophisticated instrument, cheep resources, less toxic, no resistance to them by bacteria compared with  the synthetic drugs. However the natural product will continue to be important in addition in three areas of discovery, they are a target for production by biotechnology, as source  of new lead compounds of novel chemical structure  and as the active ingredients of useful treatments divided from traditional systems of folkloric medicine(1) . The herb Loranthus Europaeus leaves and fruits was used in Iraq traditional medicine for treatment of inflammation, tumor and antimicrobial infection (2). For these reasons we tried to use the phytochemical and pharmacological studies to approache to their bioactive products as a new source for medicine. The extraction of active constituent of loranthus Europaeus (flavonoids terpenoids and alkaloids) by using chromatography method using a thimble of suxlet with different organic solvents. The ethylacetate extract contain flavonoid which contain qurcitin and quercitrin.                                 The active ingredient mixture of LE leaves extract have used as mouth wash  for 10 ladies different age have breast cancer and under treatment with chemotherapy. We found that the bioactive martial extracted from LE used as mouth wash cause cure of the inflammation of the mouth of those ladies.                                                                  In addition that 10 humans of different sexes complaining of cyst attached to one of their tooth treated with different types of antibiotic there was no response but when have given an antibiotic with bioactive agents of this LE there was complete cure of the cyst and there was no need for operation which give the possibility of presence of one or more of these (qurcitin and quercitrin) active agents act as positive nano carrier of the antibiotic to the cyst directly and cure it. In the following medicinal plant as Haloxylon, Loranthus European, Salvia, Artemesia, Ocimum sanctum microemulsion, polymeric nano  particles act as drug delivery barrier for alkaloids so which act directly on cancer cell without side effect So we can have cheap cancer drugs therapy which available from  Cheap resources and safe effective cancer therapy.

 

Meetings International - Pharmacovigilence 2020 Conference Keynote Speaker Asit Kumar Chakraborty photo

Asit Kumar Chakraborty

Asit Kumar Chakraborty, Oriental Institute of Science and Technology, Vidyasagar University, India.

Title: MDR Genes are Created and Transmitted in Plasmids and Chromosomes to Keep Normal Intestinal Microbiota Alive against High Dose Antibiotics- A Hypothesis

Biography:

Asit Kumar Chakraborty, Department of Biochemistry and Biotechnology, Oriental Institute of Science and Technology, Vidyasagar University, Midnapore-721102, West Bengal, India, Tel: 91+9339609268; E-mail: chakraakc@gmail.com
 

Abstract:

AMR spread is huge with millions of death due to ineffectiveness of antibiotics. This is happened due to creation of hundreds of mdr genes like beta-lactamases (blaTEM, blaCTX-M, blaOXA and blaNDM1), drug acetyltransferases (aacC1, aacA1, cat) and phosphotransferases (aph4) in MDR conjugative plasmids and chromosome. In other mechanisms, drug efflux proteins like tetA/C, acrAB and mexAB kickout drugs from bacterial cytoplasm increasing drug MIC and thus tetracycline, streptomycin, azithromycin, ciprofloxacin became ineffective to destroy pathogenic bacteria. We have investigated here the reason of such widespread creation of mdr genes in bacteria which are resident of intestine synthesizing 20 vitamins and complex biomolecules for our body. We have hypothesized that such 2x1012 diverse species are killed due to high dose of antibiotic intake since 1940s creating acute health hazard in human which is now balanced by probiotic bifidobacteria and vitamin-B complex capsules supplement. The hypothesis suggested that molecular signalling from intestinal luminal cells (TGFβ, IL-10, IL-22) as well as from bacteria (LPS, vitamins, butyrate) orchestrated to preserve symbiosis relation between human and bacteria. Vitamins are converted into provitamins (FADH2, NADH+, THFA, Biotin, B12, TPP etc.) needed for every steps of >30000 enzymatic reactions in human cells. Thus MDR bacteria will be the resident of intestine favouring vitamin biosynthesis and immune-modulation needed for normal human metabolosome. Indeed mdr genes are abundantly created in plasmids and chromosomes with further mutations of target genes (rRNA, ponA, porB, gyrAB, parC) and likely all are to protect gut microbiota to save human from extinct. Thus with time all bacteria will be drug resistant and infections should be controlled by heterogenous phyto-antibiotics, gene medicines, phage therapy and DNA nanocarriers for toxic drug delivery.